Skip to main content

Akebia Therapeutics, Inc.

corporate_fare Company Profile

Akebia Therapeutics, Inc.

AKBA·NASDAQ·Life Sciences·CIK 0001517022

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on developing and commercializing therapeutics for patients impacted by kidney disease. The company has two commercial products. Chronic kidney disease (CKD) is a condition where kidneys are progressively damaged, leading to waste buildup and other health problems like anemia, cardiovascular disease, and bone disease. CKD potentially affects approximately 35.5 million patients in the U.S. In 2022, treating Medicare beneficiaries with CKD in the U.S. cost an estimated $95.7 billion, and treating people on dialysis cost an estimated $45.3 billion. Akebia Therapeutics' two commercial products address certain complications of kidney disease. Its current product portfolio includes Vafseo (vadadustat), an orally administered medicine approved by the U.S. Food and Drug Administration (FDA) in March 2024. Vafseo is indicated for the treatment of anemia due to CKD in adult patients on dialysis for at least three months. The current U.S. market opportunity for treating anemia due to CKD in dialysis patients is approximately $1 billion, based on current erythropoiesis stimulating agent (ESA) pricing. Vafseo is the only oral hypoxia inducible factor (HIF) based treatment available in the U.S. Vafseo entered the market in January 2025, at which time Akebia Therapeutics had commercial supply agreements for Vafseo with dialysis organizations caring for nearly 100% of dialysis patients in the U.S.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for AKBA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for AKBA spans 10-Q, 8-K, PRE 14A, 10-K.

Recent high-impact activity:

  • Akebia Refinances BlackRock Debt With Up to $140M Symbiotic Term Loan
  • Akebia 10-Q: $36.9M Q3 Revenue, $14.4M Net Loss, and a 2027 Vafseo Revenue Warning
  • Akebia Posts $36.9M in Third-Quarter Revenue
  • Vadadustat Hits Non-Inferiority Endpoint in VOCAL, Backing Three-Times-Weekly Dosing
  • VOICE Trial Data Show Vadadustat Cuts Hospitalizations vs ESA in Dialysis Patients

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$236.2M
Net Income
-$5.34M
Diluted EPS
-$0.02
Op. Cash Flow
$67.99M
Free Cash Flow
$67.7M
Gross Profit
$196.73M
Operating Income
$23.5M
Cash & Equivalents
$184.84M
Total Debt
$48.25M
Debt / Equity
1.48×
Net Margin
-2.3%
Shares Outstanding
265.42M sh
Source: 10-K · filed 2026-02-26 · accession 0001517022-26-000020

Short Interest & Short Volume

3.01 days to cover

FINRA reported short interest of 27,204,975 shares in AKBA as of the October 30, 2026 settlement, a 17.9% increase from the prior period — about 3.0 days to cover at its recent average daily volume. On November 20, 2026, 67.0% of AKBA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)27,204,975 shares as of October 30, 2026
Change vs prior period▲ 17.9%
Days to cover3.01 at avg daily volume of 9,051,604
Daily short volume (FINRA facilities)67.0% of 2,752,808 shares on November 20, 2026
5-day average short volume61.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for AKBA, detected from its recent SEC filings · based on capital-structure filings through 2026-06-22.

Authorized Share Increase Approved · Significant Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$0.399 +3.50% today
52-week range · as of 2026-11-05 $0.399 – $2.15
Market cap
$107.04M
Volume
4.6M (0.5× avg)
3-mo avg 8.3M
Live data · 2026-11-21 19:56 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AKBA - Latest Insights

AKBA
Nov 16, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.4739
Real-time Price: $0.399 info
Change: -$0.0749 (-16%) info
Market Cap: $107.039M info
AKBA
Nov 05, 2026, 7:37 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.5199
Real-time Price: $0.399 info
Change: -$0.1209 (-23%) info
Market Cap: $107.039M info
AKBA
Nov 05, 2026, 7:10 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.69337
Real-time Price: $0.399 info
Change: -$0.29437 (-42%) info
Market Cap: $107.039M info
AKBA
Nov 05, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.69337
Real-time Price: $0.399 info
Change: -$0.29437 (-42%) info
Market Cap: $107.039M info
AKBA
Oct 26, 2026, 9:20 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.5765
Real-time Price: $0.399 info
Change: -$0.1775 (-31%) info
Market Cap: $107.039M info
AKBA
Oct 23, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.5745
Real-time Price: $0.399 info
Change: -$0.1755 (-31%) info
Market Cap: $107.039M info
AKBA
Aug 05, 2026, 4:45 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $1.06
Real-time Price: $0.399 info
Change: -$0.661 (-62%) info
Market Cap: $107.039M info
AKBA
Aug 03, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.33
Real-time Price: $0.399 info
Change: -$0.931 (-70%) info
Market Cap: $107.039M info
AKBA
Jun 30, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.15
Real-time Price: $0.399 info
Change: -$0.751 (-65%) info
Market Cap: $107.039M info
AKBA
Jun 30, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.15
Real-time Price: $0.399 info
Change: -$0.751 (-65%) info
Market Cap: $107.039M info
AKBA
Jun 22, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.09
Real-time Price: $0.399 info
Change: -$0.691 (-63%) info
Market Cap: $107.039M info
AKBA
Jun 10, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.9174
Real-time Price: $0.399 info
Change: -$0.5184 (-57%) info
Market Cap: $107.039M info
AKBA
May 07, 2026, 7:24 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.17
Real-time Price: $0.399 info
Change: -$0.7709 (-66%) info
Market Cap: $107.039M info
AKBA
May 07, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.39
Real-time Price: $0.399 info
Change: -$0.991 (-71%) info
Market Cap: $107.039M info
AKBA
May 04, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.42
Real-time Price: $0.399 info
Change: -$1.02 (-72%) info
Market Cap: $107.039M info
AKBA
Apr 15, 2026, 4:08 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $1.54
Real-time Price: $0.399 info
Change: -$1.14 (-74%) info
Market Cap: $107.039M info
AKBA
Feb 26, 2026, 7:35 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $1.34
Real-time Price: $0.399 info
Change: -$0.941 (-70%) info
Market Cap: $107.039M info
AKBA
Feb 26, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.32
Real-time Price: $0.399 info
Change: -$0.921 (-70%) info
Market Cap: $107.039M info
AKBA
Jan 12, 2026, 8:04 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.49
Real-time Price: $0.399 info
Change: -$1.09 (-73%) info
Market Cap: $107.039M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets